{"id":2979,"date":"2020-11-24T19:12:19","date_gmt":"2020-11-24T19:12:19","guid":{"rendered":"https:\/\/event.roseliassociates.com\/brain-connectivity-workshop\/?page_id=2979"},"modified":"2024-04-23T12:31:33","modified_gmt":"2024-04-23T12:31:33","slug":"agenda","status":"publish","type":"page","link":"https:\/\/event.roseliassociates.com\/pdtherapeutics\/agenda\/","title":{"rendered":"Agenda"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Agenda<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

<\/a>April 23, 2024 (Day 1)<\/span><\/h3>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Click here<\/a><\/span> for a downloadable version of the agenda. All times listed are Eastern.<\/em><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t<\/colgroup>
Welcome and Opening Remarks<\/strong><\/span><\/td><\/tr>
9:00 AM<\/strong><\/td>NINDS Welcome<\/strong>
Walter J. Koroshetz, MD<\/em>
Director, National Institute of Neurological Disorders and Stroke<\/td><\/tr>
9:10 AM<\/strong><\/td>Engaging the Lived Experience Perspective on PD Therapeutics<\/strong>
Rebekah Corlew, PhD<\/em>
Lived Experience Engagement Strategist, National Institute of Neurological Disorders and Stroke<\/td><\/tr>
Keynote Address: Landscape of PD Therapeutics Development<\/span><\/strong><\/td><\/tr>
9:20 AM<\/strong><\/td>Workshop Co-Chairs Welcome and Goals for the 2 Days<\/strong>
Alice Chen-Plotkin, MD<\/em>
Parker Family Professor of Neurology, University of Pennsylvania
Bill Martin, PhD<\/em>
Global Neuroscience Therapeutic Area Head, Johnson & Johnson Innovative Medicine<\/td><\/tr>
10:00 AM<\/strong><\/td>Break (5 minutes)<\/td><\/tr>
Session 1: PD Heterogeneity<\/strong><\/span>
Moderator<\/strong>: Karl Kieburtz, MD, MPH<\/em>, Professor, University of Rochester<\/td><\/tr>
10:05 AM<\/strong><\/td>Motor Heterogeneity in Parkinson\u2019s Disease: Challenges to Therapeutic Developments<\/span><\/span><\/strong>
Anthony Lang, MD, FRCPC<\/em>
Director, <\/span>Edmond J Safra Program in Parkinson’s Disease,<\/span><\/span> University of Toronto<\/span><\/span>\u00a0<\/span><\/td><\/tr>
10:20 AM<\/strong><\/td>Heterogeneity of Non-Motor Symptoms across Lewy Body Diseases<\/span><\/span><\/strong>
Kathleen Poston, MD, MS,<\/em>
Edward F. and Irene Thiele Pimley Professor in Neurology and Neurological Sciences,
Director, Stanford Movement Disorders Center, Stanford University<\/span><\/span>\u00a0<\/span><\/td><\/tr>
10:35 AM<\/strong><\/td>Q & A Discussion (30 minutes)<\/td><\/tr>
11:05 AM<\/strong><\/td>Break (10 minutes)<\/td><\/tr>
Session 2: Target Validation<\/strong><\/span>
Moderator<\/strong>: Alice Chen-Plotkin, MD<\/em>, Parker Family Professor of Neurology, University of Pennsylvania<\/td><\/tr>
11:15 AM<\/strong><\/td>Evolving Arcs toward Disease-Modifying Therapy for Parkinson\u2019s<\/span><\/span><\/strong>
Michael Schwarzschild, MD, PhD<\/em>
Professor of Neurology, Massachusetts General Hospital, Harvard Medical School<\/td><\/tr>
11:30 AM<\/strong><\/td>Targeting LRRK2: Why, Who, Where and When<\/strong>
Mark R. Cookson, PhD
<\/i>National Institute on Aging<\/td><\/tr>
11:45 AM<\/strong><\/td>An Industry Perspective on Target Validation <\/span>For<\/span> Neurologic Diseases<\/span><\/strong>
David Stone, PhD<\/em>
VP, Head of Genetics and Target Identification, Cerevel Therapeutics, LLC<\/td><\/tr>
12:00 PM<\/strong><\/td>Q & A Discussion (30 minutes)<\/td><\/tr>
12:30 PM<\/strong><\/td>Lunch (60 minutes)<\/td><\/tr>
Session 3: Appropriate Tools to Enable Therapeutics Development<\/span><\/strong>
Moderator<\/strong>: Shalini Padmanabhan, PhD<\/em>, Vice President, Discovery & Translational Research, Michael J. Fox Foundation<\/td><\/tr>
1:30 PM<\/strong><\/td>Teeing <\/span>U<\/span>p a <\/span>D<\/span>iscussion about <\/span>A<\/span>ppropriate <\/span>T<\/span>ools to <\/span>E<\/span>nable <\/span>T<\/span>herapeutics <\/span>D<\/span>evelopment<\/span><\/strong>
Patrik Brundin, MD, PhD<\/em>
Distinguished Scientist\/Therapeutic Area Leader for Movement Disorders, Roche<\/td><\/tr>
1:45 PM<\/strong><\/td>Preclinical<\/span> Tools to Advance Parkinson Disease Therapeutics: What They Can and Cannot Do<\/span><\/strong>
Laura Volpicelli-Daley, PhD<\/em>
Associate Professor, University of Alabama at Birmingham<\/td><\/tr>
2:00 PM<\/strong><\/td>Q & A Discussion (30 minutes)<\/td><\/tr>
2:30 PM<\/strong><\/td>Break (10 minutes)<\/td><\/tr>
Session 4: Biomarker Use<\/strong><\/span>
Moderator<\/strong>: Danielle Graham, PhD<\/em>, Head of Fluid Biomarkers and Bioanalysis, Biogen<\/td><\/tr>
2:40 PM<\/strong><\/td>AI-Enabled<\/span> Biomarkers: A Window into Parkinson’s Progression, Detection, and Treatment Response<\/span><\/strong>
Dina Katabi, PhD<\/em>
Thuan and Nicole Pham Professor, Massachusetts Institute of Technology<\/td><\/tr>
2:55 PM<\/strong><\/td>Identification of Proteomic Targets and Biomarkers: The Mapping Proteomics to Parkinson\u2019s Disease Project (MAP2PD)<\/span><\/span><\/strong>
Laura Winchester, DPhil<\/em>
Research Fellow, University of Oxford<\/td><\/tr>
3:10 PM<\/strong><\/td>Understanding Biomarker Parameters to Enable Clinical Trials in Parkinson\u2019s Disease<\/span><\/span><\/strong>
Danielle Graham, PhD<\/em>
Head of Fluid Biomarkers and Bioanalysis, Biogen<\/td><\/tr>
3:25 PM<\/strong><\/td>Q & A Discussion (30 minutes)<\/td><\/tr>
3:55 PM<\/strong><\/td>Break (15 minutes)<\/td><\/tr>
Breakout Session Day 1<\/strong><\/span><\/td><\/tr>
4:10 PM<\/strong><\/td>Parallel Breakout Session<\/strong>
What is missing that is holding back therapeutics development?<\/td><\/tr>
4:55 PM<\/strong><\/td>Break (5 minutes)<\/td><\/tr>
End of Day 1<\/strong><\/span><\/td><\/tr>
5:00 PM<\/strong><\/td>Day 1 Wrap-up<\/td><\/tr>
5:10 PM<\/strong><\/td>Adjourn for the day<\/td><\/tr><\/tbody><\/table>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

April 24, 2024 (Day 2)<\/a><\/span><\/h3>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Click here<\/a><\/span> for a downloadable version of the agenda. All times listed are Eastern.<\/em><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t<\/colgroup>
Welcome and Day 2 Opening Remarks<\/strong><\/span><\/td><\/tr>
8:45 AM<\/strong><\/td>Workshop Co-Chairs Welcome<\/strong>
Alice Chen-Plotkin, MD<\/em>
Parker Family Professor of Neurology, University of Pennsylvania
Bill Martin, PhD<\/em>
Global Neuroscience Therapeutic Area Head, Johnson & Johnson Innovative Medicine<\/td><\/tr>
Breakout Session Reports from Day 1<\/strong><\/span><\/td><\/tr>
8:55 AM<\/strong><\/td>Reports from Breakout Sessions and Q & A<\/strong>
Breakout Reports by the breakout session leaders followed by general discussion.<\/td><\/tr>
10:00 AM<\/strong><\/td>Break (10 minutes)<\/td><\/tr>
Session 5: Lessons from PD Adjacent Communities<\/span><\/strong>
Moderator<\/strong>: Amir Tamiz, PhD<\/em>, Director, Division of Translational Research, National Institute of Neurological Disorders and Stroke<\/td><\/tr>
10:10 AM<\/strong><\/td>Disease-Modifying Therapies: Lessons from Alzheimer’s Disease Drug Development<\/span><\/span><\/strong>
Jeffrey Cummings, MD, ScD<\/em>
Director, Chambers-Grundy Center for Transformative Neuroscience, University of Nevada Las Vegas, School of Integrated Health Sciences, Department of Brain Health<\/span><\/span>\u00a0<\/span><\/td><\/tr>
10:25 AM<\/strong><\/td>RNA-<\/span>T<\/span>arget <\/span>T<\/span>herapies for Neurodegenerative Disease<\/span><\/strong>
Timothy M. Miller, MD, PhD<\/em>
David Clayson Professor of Neurology, Washington University School of Medicine<\/td><\/tr>
10:40 AM<\/strong><\/td>Q & A Discussion (30 minutes)<\/td><\/tr>
11:10 AM<\/strong><\/td>Break (10 minutes)<\/td><\/tr>
Session 6: Best Practices for Advancing Development<\/strong><\/span>
Moderator<\/strong>: Bill Martin, PhD<\/em>, Global Neuroscience Therapeutic Area Head, The Janssen Pharmaceutical Companies of Johnson & Johnson<\/td><\/tr>
11:20 AM<\/strong><\/td>A<\/span><\/strong>ddressing the <\/span><\/strong>A<\/span>cademia-<\/span>I<\/span>ndustry <\/span>G<\/span>ap to <\/span>A<\/span>dvance <\/span>D<\/span>iscoveries to the <\/span>C<\/span>linic<\/span><\/strong>
Opher Kornfeld, PhD<\/em>
Director, Translational Research and Development, SPARK NS<\/td><\/tr>
11:35 AM<\/strong><\/td>LRRK2 <\/span>I<\/span>nhibitors: From Basic Biology to the Clinic<\/span><\/strong>
Anastasia Henry, PhD<\/em>
Director and Principal Scientist, Denali Therapeutics<\/td><\/tr>
11:50 AM<\/strong><\/td>Opportunities<\/span> and <\/span>C<\/span>hallenges in Parkinson\u2019s Disease <\/span>C<\/span>linical <\/span>D<\/span>evelopment using the <\/span>E<\/span>xample of the SCD <\/span>I<\/span>nhibitor YTX-7739<\/span>
<\/strong>Fiona Elwood, PhD<\/em>
VP, Disease Area Leader Neurodegeneration, Neuroscience, <\/span>Johnson & Johnson Innovative Medicine<\/span><\/span>\u00a0<\/span><\/td><\/tr>
12:05 PM<\/strong><\/td>Q & A Discussion (30 minutes)<\/td><\/tr>
End of Day 2<\/span><\/strong><\/td><\/tr>
12:35 PM<\/strong><\/td>Day 2 Wrap-up<\/td><\/tr>
12:45 PM<\/strong><\/td>Adjourn \/ Lunch (75 minutes)<\/td><\/tr>
Optional Breakout Session Day 2<\/span><\/strong><\/td><\/tr>
2:00 PM<\/strong><\/td>

Parallel breakout sessions\u00a0<\/p>

  • What to know about IP and patents, with Lauren Nguyen-Antczak<\/em>, PhD, National Cancer Institute and Susan Ano<\/em>, PhD, National Institute of Neurological Disorders and Stroke<\/span><\/li>
  • Forming partnerships with industry, with Bill Martin, Patrik Brundin, and John Sullivan<\/em>, PhD, Entrepreneur in Residence (SEED, NIH) <\/span><\/li>
  • Starting a company, with Opher Kornfeld and Leon Chen<\/em>, PhD, The Column Group <\/span><\/li><\/ul><\/td><\/tr>
3:00 PM<\/strong><\/td>Adjourn<\/td><\/tr><\/tbody><\/table>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Agenda April 23, 2024 (Day 1) Click here for a downloadable version of the agenda. All times listed are Eastern. Welcome and Opening Remarks 9:00 AM NINDS WelcomeWalter J. Koroshetz, MDDirector, National Institute of Neurological Disorders and Stroke 9:10 AM Engaging the Lived Experience Perspective on PD TherapeuticsRebekah Corlew, PhDLived Experience Engagement Strategist, National Institute…<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-2979","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/event.roseliassociates.com\/pdtherapeutics\/wp-json\/wp\/v2\/pages\/2979","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/event.roseliassociates.com\/pdtherapeutics\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/event.roseliassociates.com\/pdtherapeutics\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/event.roseliassociates.com\/pdtherapeutics\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/event.roseliassociates.com\/pdtherapeutics\/wp-json\/wp\/v2\/comments?post=2979"}],"version-history":[{"count":236,"href":"https:\/\/event.roseliassociates.com\/pdtherapeutics\/wp-json\/wp\/v2\/pages\/2979\/revisions"}],"predecessor-version":[{"id":4505,"href":"https:\/\/event.roseliassociates.com\/pdtherapeutics\/wp-json\/wp\/v2\/pages\/2979\/revisions\/4505"}],"wp:attachment":[{"href":"https:\/\/event.roseliassociates.com\/pdtherapeutics\/wp-json\/wp\/v2\/media?parent=2979"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}